ArticleEuropean journal of nuclear medicine and molecular imaging2016
[(68)Ga]NODAGA-RGD - Metabolic stability, biodistribution, and dosimetry data from patients with hepatocellular carcinoma and liver cirrhosis.
Article in European journal of nuclear medicine and molecular imaging, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 49 citations in OpenAlex.
- Advancements in Targeted Radiopharmaceuticals: Innovations in Diagnosis and Therapy for Enhanced Cancer Management.Chembiochem : a European journal of chemical biology · 2026Review
- Enhanced Radionuclide Therapy via the Conjugation of Pentadecanoic Acids WithCancer science · 2026Article
- Design and Preclinical Evaluation of aACS omega · 2025Article
- Synthesis and Preclinical Evaluation of Dual-Targeted Molecular Tracer for Positron Emission Tomography Imaging of Programmed Cell Death Ligand‑1 and Integrin αACS pharmacology & translational science · 2025Article
- Article
- Development of a Cyclic TMTP1-Based PET Probe for Visualization of Hepatocellular Carcinoma.ACS medicinal chemistry letters · 2025Article
- EGFR- and Integrin αInternational journal of molecular sciences · 2024Review
- Nano Ultrasound Contrast Agent for Synergistic Chemo-photothermal Therapy and Enhanced Immunotherapy Against Liver Cancer and Metastasis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Comparison of integrin αEuropean journal of hybrid imaging · 2023Article
- Circumsporozoite Protein ofPharmaceutics · 2022Article
- Drug delivery strategy in hepatocellular carcinoma therapy.Cell communication and signaling : CCS · 2022Review
- Synthesis, preclinical evaluation and radiation dosimetry of a dual targeting PET tracer [Theranostics · 2022Article
- Preliminary Clinical Application of RGD-Containing Peptides as PET Radiotracers for Imaging Tumors.Frontiers in oncology · 2022Review
- [European journal of nuclear medicine and molecular imaging · 2021Article
- Imaging angiogenesis in patients with head and neck squamous cell carcinomas by [European journal of nuclear medicine and molecular imaging · 2020Article
- Head and neck tumors angiogenesis imaging withEJNMMI research · 2020Article
- Radiolabelled Peptides for Positron Emission Tomography and Endoradiotherapy in Oncology.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Positron-emission tomography for hepatocellular carcinoma: Current status and future prospects.World journal of gastroenterology · 2019Review
- Berberine Facilitates Angiogenesis Against Ischemic Stroke Through Modulating Microglial Polarization via AMPK Signaling.Cellular and molecular neurobiology · 2019Article
- [Molecular imaging and biology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study was designed to determine safety, tolerability, and radiation burden of a [(68)Ga]NODAGA-RGD-PET for imaging integrin αvβ3 expression in patients with hepatocellular carcinoma (HCC) and liver cirrhosis. Moreover, metabolic stability and biokinetic data were compiled.
methodsAfter injection of 154-184 MBq [(68)Ga]NODAGA-RGD three consecutive PET/CT scans were acquired starting 8.3 ± 2.1, 36.9 ± 2.8, and 75.1 ± 3.4 min after tracer injection. For metabolite analysis, blood and urine samples were analyzed by HPLC. For dosimetry studies, residence time VOIs were placed in the corresponding organs. The OLINDA/EXM program was used to estimate the absorbed radiation dose.
resultsThe radiopharmaceutical was well tolerated and no drug-related adverse effects were observed. No metabolites could be detected in blood (30 and 60 min p.i.) and urine (60 min p.i.). [(68)Ga]NODAGA-RGD showed rapid and predominantly renal elimination. Background radioactivity in blood, intestine, lung, and muscle tissue was low (%ID/l 60 min p.i. was 0.56 ± 0.43, 0.54 ± 0.39, 0.22 ± 0.05, and 0.16 ± 0.8, respectively). The calculated effective dose was 21.5 ± 5.4 μSv/MBq, and the highest absorbed radiation dose was found for the urinary bladder wall (0.26 ± 0.09 mSv/MBq). No increased uptake of the tracer was found in HCC compared with the background liver tissue.
conclusions[(68)Ga]NODAGA-RGD uptake in the HCCs lesions was not sufficient to use this tracer for imaging these tumors. [(68)Ga]NODAGA-RGD was well tolerated and metabolically stable. Due to rapid renal excretion, background radioactivity was low in most of the body, resulting in low radiation burden and indicating the potential of [(68)Ga]NODAGA-RGD PET for non-invasive determination of integrin αvβ3 expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.